Cipla said supplies of its key US drug Lanreotide will remain constrained after its manufacturing partner paused production ...

Cipla has received the Food and Drug Administration’s blessing for lanreotide injection 120 mg/0.5 ml, 90 mg/0.3 ml, 60 mg/0.2 ml, which is the generic of somatuline depot (lanreotide) injection.

Pharma stocks rise as Cipla faces supply issues, Zydus gains FDA approval, and Biocon secures funding through a QIP.

Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia Randomized, single-blinded study. Patients with NETs received ...

MISSISSAUGA, ON, Jan. 7, 2020 /CNW/ - Ipsen Biopharmaceuticals Canada Inc. today announced the availability of a new delivery system for Somatuline ® Autogel ® (lanreotide injection) 60, 90, and 120 ...

Drug major Cipla on Sunday said it has received approval from the US health regulator to market the Lanreotide injection, used for the treatment of acromegaly and gastroenteropancreatic neuroendocrine ...

The US is the world's largest market for pharmaceutical products.

Cipla shares fell sharply on Friday after a halt in Lanreotide Injection production due to USFDA observations at its Greek partner. Supply is expected to resume in H1 FY27. The stock trades near ...

Afinitor plus Somatuline significantly improved PFS in GEP-NETs compared to Afinitor monotherapy, with median PFS of 29.7 vs. 11.5 months. The combination therapy showed a higher objective response ...